Neurotrope Inc (NASDAQ:NTRP) has earned a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Zacks has also assigned Neurotrope an industry rank of 105 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut shares of Neurotrope from a “buy” rating to a “hold” rating in a report on Friday, November 1st.
Institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in shares of Neurotrope by 144.3% during the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock worth $482,000 after purchasing an additional 35,464 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Neurotrope during the third quarter worth $28,000. Virtu Financial LLC purchased a new position in shares of Neurotrope during the third quarter worth $52,000. Morgan Stanley raised its holdings in shares of Neurotrope by 46.7% during the second quarter. Morgan Stanley now owns 20,402 shares of the company’s stock worth $164,000 after purchasing an additional 6,490 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Neurotrope by 21.7% during the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock worth $2,139,000 after purchasing an additional 47,609 shares during the last quarter. 10.03% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:NTRP traded up $0.06 on Friday, hitting $1.23. 125,633 shares of the company were exchanged, compared to its average volume of 175,258. The stock’s 50 day moving average price is $0.98 and its 200 day moving average price is $2.61. Neurotrope has a 1-year low of $0.63 and a 1-year high of $8.40. The firm has a market capitalization of $15.29 million, a P/E ratio of -0.86 and a beta of 1.98.
Neurotrope (NASDAQ:NTRP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03.
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Further Reading: What is a stock split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.